Lonza Invests CHF 20 million to Expand API Development and Manufacturing Facility in Nansha, China

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Bavarian Nordic Agrees for a $3 Bn Take-Private Offer

Bavarian Nordic, the vaccine maker, on July 28 said...

South Korea – A Biopharma Innovation Hub With 113% Growth

The biopharmaceutical sector of South Korea has seen a...

Vinay Prasad Leaves the FDA – An Abrupt End to His Tenure

The head of the Food and Drug Administration office,...

Resistance-Evasive Antibiotic for Genes-Free Clinics

In a startling figure, multidrug-resistant bacteria kill almost 5...

Lonza announced new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over CHF 20 million, will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for customers while maintaining Lonza’s global quality and regulatory standards.

The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. The additional GMP laboratories will be able to develop and manufacture highly potent API (HPAPI) under GMP standards.

Lonza’s Nansha site is fully integrated within the company’s global manufacturing network. Scientists and engineers based in Nansha focus on API development and manufacturing for customers around the globe. The Lonza team also contains regulatory specialists with experience working with Chinese regulators throughout the drug development and scale-up process. Approximately 250 employees work at Lonza’s Nansha site; this expansion is expected to create around 70 new positions.

The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022.

Latest stories

Related stories

Bavarian Nordic Agrees for a $3 Bn Take-Private Offer

Bavarian Nordic, the vaccine maker, on July 28 said...

South Korea – A Biopharma Innovation Hub With 113% Growth

The biopharmaceutical sector of South Korea has seen a...

Vinay Prasad Leaves the FDA – An Abrupt End to His Tenure

The head of the Food and Drug Administration office,...

Resistance-Evasive Antibiotic for Genes-Free Clinics

In a startling figure, multidrug-resistant bacteria kill almost 5...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back